Fluidigm Corp. (NASDAQ: FLDM) today announced it has completed its acquisition of DVS Sciences, Inc. With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms to create a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.
DVS’s principal product is the CyTOF® 2 Mass Cytometer, which analyzes antibody/metal complexes using atomic mass spectrometry. The technology enables high-parameter single-cell protein analysis for applications in biological research. Several members of DVS’s management, operations and research and development teams – including co-founders Scott Tanner, Dmitry Bandura, and Vladimir Baranov – are joining Fluidigm to drive the integration of the organizations and support the continued growth of the combined business.
“As evidenced by its products, technology, people and business trajectory, DVS is an extraordinary company. We are thrilled to have it become part of Fluidigm,†said Gajus Worthington, Fluidigm President and Chief Executive Officer. “2013 was an incredible year for Fluidigm as we took our business and scientific influence to a new level. Now we are doubling our efforts to take our newly combined company and collective capabilities to new heights. Fluidigm now offers a comprehensive portfolio of genomic and proteomic solutions for this new and very exciting field of single-cell biology.â€
DVS Sciences, Inc., with its principal operations in Sunnyvale, California, is now a wholly-owned subsidiary of Fluidigm. DVS Sciences Inc., a Canadian corporation with principal operations in Toronto, Ontario, remains a wholly owned subsidiary of DVS Sciences, Inc.
SOURCEÂ Fluidigm Corp.